YOUR SEARCH FOR Text 31 RESULTS
11 of Total
Contact Us | Incyte.com.com
… field. E-mail Required field. Invalid Email address Last Name 20 character(s) left Required …
12 of Total
Pioneering Progress: The Evolution of Dermatology at Incyte | Incyte Stories
… respectively, we are expanding our efforts to address additional diseases and explore new …
13 of Total
Incyte Involved | Supporting Our Communities | Incyte.com
… and signed W-9 form (organization name and address must match funding request form) is …
14 of Total
What Can JAK Inhibition Do? More Than You Might Think | Incyte.com
… potential applications for JAK inhibition that address significant unmet patient needs beyond …
15 of Total
Terms of Use | Incyte.com
… the website or any of Incyte’s email or other addresses to send Incyte proprietary or …
16 of Total
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced An
… for patients facing this challenging disease, addressing a significant unmet need in cancer …
17 of Total
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advance
… CHMP opinion is an important step towards addressing the urgent need for new treatment …
18 of Total
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapse
… systemic therapy. " The EC approval of Minjuvi addresses a critical need, bringing a new, …
19 of Total
… per share (b) Name of Issuer: Incyte Corp (c) Address of Issuer's Principal Executive Offices: …
20 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs August 3, 2021 at 8:00 AM EDT PDF